1,721,009 research outputs found
The determination of tenofovir level in breast milk of nursing mothers under tenofovir therapy
No full textAnnual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting -- NOV 09-13, 2018 -- San Francisco, CAWOS: 000446020500434In this study, we aimed to determine of tenofovir concentration in maternal plasma, breast milk and plasma of infants and factors affecting drug levels in chronic hepatitis B (CHB) patients using tenofovir disoproxil fumarate (TDF) during breastfeeding period.American Association for the Study of Liver Disease
Clinical trial watch: Reports from the AASLD Liver Meeting®, Boston, November 2014
No full textSummaryThe late and fast developments in the field of viral hepatitis were highly expected in the 2014 AASLD Liver Meeting®. Several combinations using direct acting antivirals (DAAs) showed high rates of sustained virological response (∼95%). Importantly, high cure rates were also demonstrated in patients with previous treatment failures, decompensated cirrhosis and hepatitis C recurrence after transplantation, making it clear that the interferon era is over (not so clear for ribavirin, which might still have a role in difficult-to-treat populations). Importantly, sustained virological response was associated with an improvement in liver function (MELD and Child-Pugh scores) in patients with advanced liver disease. In the field of liver cirrhosis, there were relevant data assessing the optimal empirical antibiotic therapy in patients with spontaneous bacterial peritonitis and high risk of resistant bacteria, as well as studies evaluating the role of terlipressin in type I hepatorenal syndrome and in septic shock. Regarding hepatic encephalopathy, two randomized trials suggest that the manipulation of the microbioma in patients with cirrhosis may have a role in the management of this complication. Some novel data on NASH support the beneficial effect of bariatric surgery (after failure of lifestyle intervention) in morbid obese patients with such diagnosis: clinical and histological improvements after surgery were evident in most patients with sufficient follow-up. A few controlled studies focused on the treatment of severe acute alcoholic hepatitis. Finally, several studies on hepatocellular carcinoma (HCC) were presented, covering topics such as ultrasound screening in cirrhosis, cryoablation treatment of early HCC and the relevance of downstaging in patients with HCC awaiting liver transplantation
Roman Liver Tx Allocation: Results at 48 months of an innovative regional allocationmodel based on MELDNa and Donor-to-Recipient Match
No full textRoman Liver Tx Allocation: Results at 48
months of an innovative regional allocation
model based on MELDNa and Donor-to-Recipient
Match
Federica Ferracci1, Alfonso W. Avolio1, Francesca R. Ponziani1,
Antonio Grieco1, Salvatore Agnes1, Stefano Ginanni
Corradini2, Fabio Melandro2, Flaminia Ferri2, Massimo Rossi2,
Tommaso M. Manzia3, Ilaria Lenci3, Matteo Manuelli3,
Mario Angelico3, Giuseppe Tisone3, Giovanni Vennarecci4,
Marco Colasanti4, Roberto L. Meniconi4, Ubaldo Visco Comandini4,
Giuseppe M. Ettorre4, Raffaella Zaccaria5, Nicola Torlone5,
Maurizio Valeri5; 1Transplant center - University Hospital
“A. Gemelli”, Rome, Italy; 2Transplant center - University Hospital
“Umberto I”, Rome, Italy; 3Transplant center - University
Hospital “Tor Vergata”, Rome, Italy; 4Transplant center - San
Camillo Hospital, Rome, Italy; 5Transplant center - Regione
Lazio, Rome, Italy
BACKGROUND Liver allocation policies are different
between Countries and regions. An innovative allocation
model based on MELDNa and donor age was developed
in Italy in a donor-to-recipient match perspective. 244
Liver transplants (LT) performed (2013-2015) in a 4 Center
regional Consortium were compared to 235 controls (2010-
2012). P&M In the 2013-2015 period, Standard Organs
(SO, N=151, 61,8%) were allocated to patients (pts) on a
common regional waiting list, based on MELDNa (5 classes:
>30, N=32, 13.2%; 29-24, N=41, 16.8%; 23-20, N=19, 7.8%;
19-15, N=24, 9.8%; <15, N=35, 14.3%). Non-SO (donor age
>65, N=76, 31.2%;other reasons, N=17, 6.9%) were allocated
locally, according to priority defined in each Center. and
to individual patient’s characteristics (mainly HCC pts
with progressive disease). In the 2010-2012 period each
Center used a MELD based allocation algorithm and HCC
pts were equipoised to non-HCC pts using the MELD 22
rule. Univariate Kaplan Meier (KM) and multivariate Cox
analyses (Cox) were used. RESULTS LT in 2013-2015 period
were older, with higher MELDNa, and received organs by
older donors. Regarding non-HCC patients: Recipient’s
age: 52±11 vs 50±11; Donor’s age: 51±18 vs 52±18; MELD
at LT: 23±7 vs 21±7, p=0.002; MELDNa at LT: 25±7 vs 22±7,
p=0.003. Regarding HCC patients: Recipient’s age: 58±6
vs 57±8; Donor’s age: 56±17 vs 52±18; MELD at LT: 15±6
vs 14±6; MELDNa at LT: 16±7 vs 15±5. Waiting time was
significantly lower for non-HCC group 2.0±4.4 vs 6.7±8.3
mo, p=0.0001, and unchanged for the HCC patients
5.7±5.2 vs 5.3±5. 48 mo patient survival was similar (KM:
overall 76% continuos l vs 79% dotted l; non-HCC: 78%
vs 80%; HCC: 73% vs 77%). MELDNa and recipient’s age
resulted significant prognostic predictors at Cox. CONCLUSIONS
Although overall survival was slightly reduced in the
non-SO HCC subgroup, the innovative allocation model
provides positive results about overall LT performed, using
organs from older donors, and faster transplantation for
pts with progressive liver disease
CD40L enrichment of hepatic exosomes augment IL-17A production of gd T cells by regulating hepatic stellate cells and Kupffer cells in alcoholic liver disease
No full textOUTCOMES WITH ODEVIXIBAT TREATMENT IN PATIENTS WITH ALAGILLE SYNDROME: ANALYSIS OF PRURITUS RESPONDERS FROM THE PHASE 3 ASSERT STUDY
No full textEnclose
INDIVIDUAL PRURITUS AND BILE ACID RESPONSES OVER TIME WITH ODEVIXIBAT TREATMENT: POOLED DATA FROM THE PHASE 3 ASSERT AND ASSERT-EXT STUDIES IN PATIENTS WITH ALAGILLE SYNDROME
No full textEnclose
Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)
No full text68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, DC, OCT 20-24, 2017International audienc
Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)
No full text68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, DC, OCT 20-24, 2017International audienc
Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)
No full text68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, DC, OCT 20-24, 2017International audienc
A Community-Led Research Model for Qualitative Evaluation of Access to and Quality of HCV Services in Five Middle Income Countries (2018)
No full textAnnual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc
- …
